Neutrophil dynamics after chemotherapy and G-CSF: The role of pharmacokinetics in shaping the response

Journal of Theoretical Biology

Volumn 315, Issue , 2012, Pages 97-109

  Brooks, Grace ^a   Provencher, Gabriel ^a   Lei, Jinzhi ^b   Mackey, Michael C ^a  

^a MCGILL UNIVERSITY   (Canada)

^b TSINGHUA UNIVERSITY   (China)

Author keywords

Cancer; Mathematical model; Neutropenia; Recovery rate; Resonance

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR;

BLOOD; CANCER; CHEMOTHERAPY; NUMERICAL MODEL; RESONANCE;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL PROTOCOL; COMPARTMENT MODEL; CONTROLLED STUDY; DISEASE EXACERBATION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG INFUSION; DRUG RESPONSE; DYNAMICS; FEEDBACK SYSTEM; MATHEMATICAL MODEL; NEUTROPENIA; NEUTROPHIL; NEUTROPHIL COUNT; PHARMACOKINETICS; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEADY STATE;

ANTINEOPLASTIC AGENTS; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MODELS, IMMUNOLOGICAL; NEUTROPHILS; NUMERICAL ANALYSIS, COMPUTER-ASSISTED;

EID: 84866845638     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2012.08.028     Document Type: Article

References (74)

1. Abkowitz J.L., Golinelli D., Harrison D.E., Guttorp P. In vivo kinetics of murine hemopoietic stem cells. Blood 2000, 96:3399-3405.
2. Andersen L.K., Mackey M.C. Resonance in periodic chemotherapy. a case study of acute myelogenous leukemia. J. Theor. Biol. 2001, 209:113-130.
3. Bernard S., Pujo-Menjouet L., Mackey M.C. Analysis of cell kinetics using a cell division marker. mathematical modeling of experimental data. Biophys. J. 2003, 84:3414-3424.
4. Bernard S., Bélair J., Mackey M.C. Oscillations in cyclical neutropenia. new evidence based on mathematical modeling. J. Theor. Biol. 2003, 223:283-298.
5. Boggs D., Boggs S., Saxe D., Gress L., Canfield D. Hematopoietic stem cells with high proliferative potential assay of their concentration in marrow by the frequency and duration of cure of W/Wv mice. J. Clin. Invest. 1982, 70:242-253.
6. Butler R.D., Waites T.M., Lamar R.E., Hainsworth J.D., Greco F.A., Johnson D.H. Timing of G-CSF administration during intensive chemotherapy for breast cancer (abstract). Am. Soc. Clin. Oncol. 1992, 11:1411.
7. Colijn C., Mackey M.C. A mathematical model of hematopoiesis. I periodic chronic myelogenous leukemia. J. Theor. Biol. 2005, 237:117-132.
8. Colijn C., Mackey M.C. A mathematical model of hematopoiesis. II. Cyclical neutropenia. J. Theor. Biol. 2005, 237:133-146.
9. Colijn C., Foley C., Mackey M.C. G-CSF treatment of canine cyclical neutropeina. a comprehensive mathematical model. Exp. Hematol. 2007, 37:898-907.
10. Crawford J., Dale D.C., Lyman G.H. Chemotherapy-induced neutropenia. risks, consequences, and new directions for its management. Cancer 2003, 100:228-237.
11. Dale, David C., Alling, David W., Wolff, Sheldon M., 1973. Application of time series analysis to serial blood neutrophil counts in normal individuals and patients receiving cyclophosphamide. Br. J. Haematol., 24(1), 57-64.
12. Dancey J.T., Deubelbeiss K.A., Harker L.A., Finch C.A. Neutrophil kinetics in man. J. Clin. Invest. 1976, 58:705-715.
13. Engel C., Scholz M., Loeffler M. A computational model of human granulopoiesis to simulate the hematotoxic effects of multicycle polychemotherapy. Blood 2004, 104(8):2323-2331.
14. Fetterly, Gerald J., Grasela, Thaddeus H., Sherman, Jeffrey W., Dul, Jeanne L., Grahn, Amy, Lecomte, Diane, Fiedler-Kelly, Jill, Damjanov, Nevena, Fishman, Mayer, Kane, Michael P., Rubin, Eric H., Tan, Antoniette R, 2008. Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase 1 development of liposome-entrapped Paclitaxel. Clin. Cancer Res. 14, 5856-5863.
15. Fogli, S., Danesi, R., Braud, F. De, Pas, T. De, Curigliano, G., Giovannetti, E., Tacca, M. Del. 2001. Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemciabine in patients with non-small-cell lung cancer. Ann. Oncol. 12, 1553-1559.
16. Foley C., Mackey M.C. Mathematical model for G-CSF administration after chemotherapy. J. Theor. Biol. 2009, 257:27-44.
17. Foley C., Bernard S., Mackey M. Cost-effective G-CSF therapy strategies for cyclical neutropenia. mathematical modelling based hypotheses. J. Theor. Biol. 2006, 238:754-763.
18. Fukuda M., Nakato M., Kinoshita A., et al. Optimal timing of G-CSF administration in patients receiving chemotherapy for non-small cell lung cancer (NSCLC) (abstract). Am. Soc. Clin. Oncol. 1993, 12:1549.
19. Gianni L., Kearns C.M., Giani A., Capri G., Vigano L., Locatelli A., Bonadonna G., Egorin M.J. Nonlinear pharmacokinetics and metabolisn of Paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol. 2011, 13:180-190.
20. Green M.D., Koelbl H., Baselga J., Galid A., Guillem V., Gascon P., Siena S., Lalisang R.I., Samonigg H., Clemens M.R., Zani V., Liang B.C., Renwick J., Piccart M.J. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann. Oncol. 2003, 14:29-35.
21. Harrison D., Astle C., Lerner C. Number and continuous proliferative pattern of transplanted primitive immunohematopoietic stem cells. Proc. Natl. Acad. Sci. USA 1988, 85:822-826.
22. Haurie C., Dale D.C., Rudnicki R., Mackey M.C. Modeling complex neutrophil dynamics in the grey collie. J. Theor. Biol. 2000, 24:505-519.
23. Hearn T., Haurie C., Mackey M.C. Cyclical neutropenia and the peripherial control of white blood cell production. J. Theor. Biol. 1998, 192:167-181.
24. Henningsson A., Karlsson M.O., Viganó L., Gianni L., Verweij J., Sparreboom A. Mechanism-based pharmacokinetic model for paclitaxel. J. Clin. Oncol. 2001, 19:4065-4073.
25. Israels L.G., Israels E.D. Mechanisms in Hematology 2002, Core Health Services Inc.
26. Karl S., Häckerand S., Mader I., Cristofanon S., Schweitzer T., Krauss J., Rutkowski S., Debatin K.-M., Fulda S. Histone deacetylase inhibtors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation. Oncogene 2011, 30:2275-2281.
27. Kennedy B.J. Cyclic leukocyte oscillations in chronic myelogenous leukemia during hydroxyurea therapy. Blood 1970, 35(6):751-760.
28. Kiani A., Köhne C.-H., Franz T., Passauer J., Haufe T., Gross P., Ehninger G., Schleyer E. Pharmacokinetics of gemcitabine in a patient with end-stage renal disease. effective clearance of its main metabolite by standard hemodialysis treatment. Cancer Chemother. Pharmacol. 2003, 51:226-270.
29. Koumakis G., Vassilomanolakis M., Barbounis V., Hatzichristou E., Demiri S., Platanoiotis G., Pamouktsoglou F., Efrmidis A. Optimal timing (preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cytophosphamide. Oncology 1999, 56:28-35.
30. Layton J.E., Hall N.E. The interaction of G-CSF with its receptor. Front. Biosci. 2006, 11:3181-3189.
31. Leavey P.J., Sellins K.S., Thurman G., Elzi D., Hiester A., Silliman C.C., Zerbe G., Cohen J.J., Ambruso D.R. In vivo treatment with granulocyte colony-stimulating factor results in divergent effects on neutrophil functions measured in vitro. Blood 1998, 92:4366-4374.
32. Lei J., Mackey M.C. Multistability in an age-structured model of hematopoiesis. cyclical neutropenia. J. Theor. Biol. 2011, 270:143-153.
33. Levine M.N., Whelan T. Adjuvant chemotherapy for breast cancer-30 years later. N. Engl. J. Med. 2006, 355:1920-1922.
34. MacDonald, N., 1978. Cyclical neutropenia: models with two cell types and two time lags. In: Valleron, A.J., Macdonald, P.D.M. (Eds), Biomathematics and Cell Kinetics. Amsterdam: Elsevier/North-Holland, Amsterdam.
35. MacDonald N. Biological Delay Systems. Linear Stability Theory 1989, Cambridge University Press, Cambridge.
36. Mackey M.C. Cell kinetic status of hematopoietic stem cells. Cell Prolif. 2001, 34:71-83.
37. McCarthy K.F. Population size and radiosensitivity of murine hematopoietic endogenous long-term repopulating cells. Blood 1997, 89:834-841.
38. Meisenberg B.R., Davis T.A., Melaragno A.J., Stead R., Monroy R.L. A comparison of therapeutic schedules for administering granulocyte colony-stimulating factor to nonhuman primates after high-dose chemotherapy. Blood 1992, 79:2267-2272.
39. Merchant A.A., Singh A., Matsui W., Biswal S. The redox-sensitive transcription factor Nrf2 regulates murine hematopoietic stem cell survival independently of ROS levels. Blood 2011, 118(25):6572-6579.
40. Micklem H., Lennon J., Ansell J., Gray R.A. Numbers and dispersion of repopulating hematopoietic cell clones in radiation chimeras as functions of injected cell dose. Exp. Hematol. 1987, 15:251-257.
41. Minkin P., Zhao M., Chen Z., Ouwerkerk J., Gelderblom H., Baker S.D. Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2008, 874:84-88.
42. Morikawa N., Mori T., Abe T., Ghoda M., Takeyama M., Hori S. Pharmacokinetics of methotrexate in plasma and cerebrospinal fluid. Ann. Pharmacother. 1997, 31:1153-1156.
43. Morstyn G., Campbell L., Lieschke G., Layton J.E., Maher D., O'Connor M., Green M., Sheridan W., Vincent M., Alton K., Souza L., McGrath K., Fox R.M. Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J. Clin. Oncol. 1989, 7:1554-1562.
44. Mou C., Ganju N., Sridhar K.S., Krishan A. Simultaneous quantitation of plasma doxorubicin and prochlorperazine content by high-performance liquid chromatography. J. Chromatogr. B 1997, 703:217-224.
45. Novak J.P., Nečas E. Proliferation differentiation pathways of murine haematopoiesis. correlation of lineage fluxes. Cell. Prolif. 1994, 27:597-633.
46. Oguri S., Sakakibara T., Mase H., Shimiuzu T., Ishikawa K. Clinical pharmacokinetics of carboplatin. J. Clin. Pharmacol. 1988, 28(3):208-215.
47. Oostendorp R.A., Audet J., Eaves C.J. High-resolution tracking of cell division suggests similar cell kinetics of hematopoietic stem cells simulated in vitro and in vivo. Blood 2000, 95:855-862.
48. Østby I., Rusten L.S., Kvalheim G., Grøttum P. A mathematical model of reconstitution of granulopoiesis after high dose chemotherapy with autologous stem cell transplantation. J. Math. Biol. 2003, 47:101-136.
49. Østby I., Kvalheim G., Rusten L.S., Grottum P. Mathematical modeling of granulocyte reconstitution after high-dose chemotherapy with stem cell support. effect of posttransplant G-CSF treatment. J. Theor. Biol. 2004, 231:69-83.
50. Østby, Ivar, Winther, Ragnar. 2004. Stability of a model of human granulopoiesis using continuous maturation. J. Math. Biol., 49(5), 501-536.
51. Peng B., Hayes M., Resta D., Racine-Poon A., Druker B.J., Talpaz M., Sawyers C.L., Rosamilia M., Ford J., Lloyd P., Capdeville R. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J. Clin. Oncol. 2004, 22:935-942.
52. Perry S., Moxley J.H., Weiss G.H., Zelen M. Studies of leukocyte kinetics by liquid scintillation counting in normal individuals and in patients with chronic myelogenous leukemia. J. Clin. Invest. 1966, 45:1388-1399.
53. Price T.H., Chatta G.S., Dale D.C. Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood 1996, 88:335-340.
54. Rahman Z., Esparza-Guerra L., Yap H.Y., Fraxchini G., Bodey G., Hortobagyi G. Chemotherapy-induced neutropenia and fever in patients with metastasic breast carcinoma receiving salvage chemotherapy. Cancer 1997, 79:1150-1157.
55. Rubinow S., Lebowitz J. A mathematical model of neutrophil production and control in normal man. J. Math. Biol. 1975, 1:187-225.
56. Schmitz S., Franke H., Brusis J., Wichmann H.E. Quantification of the cell kinetic effect of G-CSF using a model of human granulopoiesis. Exp. Hematol. 1993, 21:755-760.
57. Schmitz S., Franke H., Loeffler M., Wichmann H.E., Diehl V. Model analysis of the contrasting effects of GM-CSF and G-CSF treatment on peripheral blood neutrophils observed in three patients with childhood-onset cyclic neutropenia. Br. J. Haematol. 1996, 95:616-625.
58. Scholz M., Engel C., Loeffler M. Modelling human granulopoiesis under poly-chemotherapy with G-CSF support. J. Math. Biol. 2005, 50:397-439.
59. Shankar A., Wang J., Rochtchina E., Yu M.C., Kefford R., Mitchell P. Association between circulating white blood cell count and cancer mortality. a population-based cohort study. Arch. Intern. Med. 2006, 166:188-194.
60. Shochat E., Rom-Kedar V. Novel strategies for granulocyte colony-stimulated factor treatment of severe prolonged neutropenia suggested by mathematical modeling. Clin. Cancer Res. 2008, 14:6354-6363.
61. Shochat E., Rom-Kedar V., Segel L.A. G-CSF control of neutrophil dynamics in the blood. Bull. Math. Biol. 2007, 69:2299-2338.
62. Skeel, Roland T. (Ed.), 2007. Handbook of Cancer Chemtherapy, 7th edn. Lippincott Williams & Wilkins.
63. Sola, Martha C., Du, Yan, Hutson, Alan D., & Christensen, Robert D. 2000. Dose-response relationship of mekagaryocyte progenitors from the bone marrow of thrombocytopenic and non-thrombocytopenic neonates to recombinant thrombopoietin. Br. J. Haematol. 110, 449-453.
64. Sparreboom A., Wolff A., Verweij J. Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood. Clin. Cancer Res. 2003, 9:151-159.
65. Steinbach K.H., Schick P., Trepel F., Raffler H., Dohrmann J., Heilgeist G., Heltzel W., Li K. Estimation of kinetic parameters of neutrophilic, eosinophilic, and basophilic granulocytes in human blood. Blut 1979, 39:27-38.
66. Steinbach K.H., Raffler H., Pabst G., Fliedner T.M. A mathematical model of canine granulopoiesis. J. Math. Biol. 1980, 10(1-12).
67. Thatcher N., Girling D.J., Hopwood P., Sambrook R.J., Qian W., Stephens R.J. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support. results of a British medical research council multicenter randomized trial. J. Clin. Oncol. 2000, 18:395-404.
68. Tjan-Heijnen V.C.G., Wagener D.J.T., Postmus P.E. An analysis of chemotherapy dose and dose-intensity in small-cell lung cancer. lessons to be drawn. Ann. Oncol. 2002, 13:1519-1530.
69. Vainstein V., Ginosar Y., Shoham M., Ranmar D., Ianovski A., Agur Z. The complex effect of granulocyte colony-stimulating factor on human granulopoiesis analyzed by a new physiologically-based mathematical model. J. Theor. Biol. 2005, 234:311-327.
70. Vainstein V., Ginosar Y., Shoham M., Ranmar D.O., Ianovski A., Agur Z. The complex effect of granulocyte colony-stimulating factor on human granulopoiesis analyzed by a new physiologically-based mathematical model. J. Theor. Biol. 2005, 234:311-327.
71. Wheldon T.E. Mathematical models of oscillatory blood cell production. Math. Biosci. 1975, 24:289-305.
72. Wheldon T.E., Kirk J., Finlay H.M. Cyclical granulopoiesis in chronic granulocytic leukemia. a simulation study. Blood 1974, 43:379-387.
73. Wichmann H.E., Loeffler M. Mathematical Modeling of Cell Proliferation. Stem Cell Regulation in Hemopoiesis 1985, CRC Press, Boca Raton.
74. Zhuge C., Lei J., Mackey M.C. Neutrophil dynamics in response to chemotherapy and G-CSF. J. Theor. Biol. 2012, 293:111-120.